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Abstract
Background: The potential utility of dendritic cells (DC) as cancer vaccines has been established in early trials in
human cancers. The concomitant administration of cytotoxic agents and DC vaccines has been previously avoided
due to potential immune suppression by chemotherapeutics. Recent studies show that common chemotherapy
agents positively influence adaptive and innate anti-tumour immune responses.
Results: We investigated the effects of paclitaxel on human DC biology in vitro. DCs appear to sustain a significant
level of resistance to paclitaxel and maintain normal viability at concentrations of up to 100 μmol. In some cases
this resistance against paclitaxel is significantly better than the level seen in tumour cell lines. Paclitaxel exposure
led to a dose dependent increase in HLA class II expression equivalent to exposure to lipopolysaccharide (LPS), and
a corresponding increase in proliferation of allogeneic T cells at the clinically relevant doses of paclitaxel. Increase
in HLA-Class II expression induced by paclitaxel was not blocked by anti TLR-4 antibody. However, paclitaxel
exposure reduced the endocytic capacity of DC but reduced the expression of key pro-inflammatory cytokines
such as IL-12 and TNFa. Key morphological changes occurred when immature DC were cultured with 100 μmol
paclitaxel. They became small rounded cells with stable microtubules, whereas there were little effects on LPS-
matured DC.
Conclusions: The effect of paclitaxel on human monocyte derived DC is complex, but in the clinical context of
patients receiving preloaded and matured DC vaccines, its immunostimulatory potential and resistance to direct
cytotoxicity by paclitaxel would indicate potential advantages to co-administration with vaccines.
Background
Dendritic cells (DC) are specialized antigen presenting
cells that can initiate a primary immune response on
encountering foreign antigens [1]. There has been much
focus aimed at harnessing their potency in several clini-
cal applications including cancer, infectious and inflam-
matory diseases [2-4]. However, there has been limited
success in the treatment of many cancers using dendri-
tic cell based immunotherapy [5]. DC are capable of
ingesting dead and dying (apoptotic) tumour cells which
potentially expose the DC to an array of tumour-asso-
ciated antigens for processing and presentation to
T cells via HLA class I and II pathways [6-8]. Whilst
several methods for loading DC ex vivo with tumour
antigens are currently used, including DNA, RNA,
peptides and apoptotic tumour cells, the optimal
approach has yet to be determined. The reasons why
individual loading strategies may fail to successfully
induce anti-tumour immunity are still not fully under-
stood. However, an understanding of the natural
mechanisms by which DC acquire tumour antigens and
mature in situ has resulted in the improvement of sev-
eral DC-based immunotherapy strategies.
It has been proposed that in situ destruction of
tumour cells using chemotherapy, radiotherapy or other
physical methods releases suitable antigenic material
which can lead to enhanced antigen acquisition and sti-
mulation of an immune response [9]. The chemothera-
peutic agent paclitaxel (Paclitaxel) induces cancer cell
death by promoting the polymerisation of tubulin,
thereby causing cell death and apoptosis by disrupting
the normal microtubule dynamics required for cell divi-
sion [10]. Paclitaxel has been shown to be highly
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evidence to show that systemic administration of cyto-
toxic compounds such as paclitaxel can have a detri-
mental effect on the number of systemic DC [11].
However, at lower concentrations there is also evi-
dence to suggest that paclitaxel may be immunostimula-
tory which may contribute to the overall antitumour
effects in the clinical setting [12-17]. Several murine
cancer models have demonstrated that combined che-
motherapy and DC-based immunotherapy can lead to
complete tumour regression in contrast to partial
regression in response to each element used individually
[18].
The maturation status of DC is a key factor required
for the induction of a specific immune response and is
reliant on the presentation of antigens by fully mature
DC. Paclitaxel has been shown to interact with TLR-4, a
know receptor for lipopolysaccharide (LPS), on murine
myeloid cells [19,20]. However, the effects of paclitaxel
on DC maturation remain to be clarified.
The aims of this study were to evaluate the immuno-
modulatory effects of paclitaxel applied to ex vivo gener-
ated DC in terms of phenotype, function and cytokine
expression. The findings of this study may have impor-
tant implications in treating malignancies with che-
motherapy and concomitant administration of ex vivo
DC.
Results
MTS assay of melanoma cell and DC mitochondrial
activity
In clinical practice chemotherapy exposes both tumour
cells and the cells of the immune system to the cyto-
toxic potential of the drug. A common target in either
cell type is cytoplasmic mitochondrial function. The
potency for inhibition of this activity can be reliably
demonstrated using the MTS/PMS assay. The human
breast adenocarcinoma cell line MCF7-pR has been
shown to be sensitive to paclitaxel both in vitro and
in vivo in tumour models [21]. The cytoxicity of this
and other chemotherapeutic compounds on the newly
established melanoma cell line MJT-3 has been pre-
viously demonstrated in our laboratory (unpublished
data). Figure 1 shows that both MCF7-pR and MJT-3
cell lines are sensitive to paclitaxel over a wide range on
concentrations from 0.05 to 1000 μmol. DC were less
sensitive to paclitaxel than MCF7-pR, with around 60%
difference in mitochondrial activity, and marginally
more sensitive than MJT-3 tumour cell lines with a dif-
ference of nearly 20% when treated with 0.05 μmol.
Correlation of DC viability by TB and PI staining
DC were incubated with paclitaxel as in the MTS/PMS
assay but were analysed for viability and membrane
integrity by employing TB dye exclusion by microscopy
and PI exclusion by flow cytometry (data not shown).
As can be seen in figure 2A, DC viability by PI exclusion
was maintained even when the DC were exposed to
Paclitaxel for 2 h at concentrations up to 100 μMa n d
returned to culture for up to 5 days.
At least 80% viability was maintained when DC were
continuously exposed to paclitaxel for 24 h and 48 h at
concentration below 100 μM. However, when DC were
exposed to paclitaxel at 100 μM for 48 h there is a sig-
nificant decrease of viability to around 60%, figure 2B.
In comparison, DC exposed to LPS for the same dura-
tion of the experiment maintained their viability, consis-
tent with reports of LPS inducing a survival signal to
DC [22].
Phenotypic changes of DC treated with Paclitaxel
The resistance of DC to paclitaxel at concentrations up
to 100 μM was also reflected in surface marker expres-
sion by flow cytometry. As outlined in Table 1 the addi-
tion of paclitaxel led to the dose dependent increase in
the expression of HLA class II molecules (Table 1) i.e.
the MFI for the cells treated with 1, 10 or 100 μMw a s
690, 888 1109 respectively. The expression levels of
Class II on paclitaxel-treated DC at 100 μMw e r e
equivalent to that induced by LPS. Higher concentra-
tions of paclitaxel (1 mM) did not permit analysis of
class II expression due to DC viability being too low for
Figure 1 Paclitaxel inhibits mitochondrial activity in tumour
cell lines and DC as assessed by MTS/PMS assay. Tumour cell
lines MJT-3 (black squares), MCF7-pR (grey squares) and DC (white
squares) were incubated with paclitaxel for 2 h before being
washed and returned to culture for 48 h. Sensitivity was determined
by the addition of MTS/PMS for triplicate samples ± SD. Each
experiment was repeated 3 times and DC from 3 individual donors
evaluated. Representative histograms from one experiment are
shown. At lower doses (up to 0.5 μmol) of paclitaxel, the DC are
more resistant than tumour cells (p value = 0.003). DC were more
resistant overall than MCF7-pR.
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effects on co-stimulatory molecule expression or on
CD209 or CD197.
Enhanced DC stimulatory capacity at low dose paclitaxel
The immunostimulatory properties of Paclitaxel-treated
DC were assessed by studying their ability to induce the
proliferation of allogeneic T cells. The addition of pacli-
taxel at a concentration of 100 μM did not significantly
alter the ability of DC to induce proliferation when
compared to non-treated counterparts. Higher concen-
trations of paclitaxel (1 mM) totally abolished prolifera-
tion indicative of toxicity to the DC at the higher dose
(figure 3). The stimulatory effect of 1 μMa n d1 0μM
doses of paclitaxel on DC was significantly higher
(p < 0.05) when compared to LPS matured DC and
Figure 2 (A) DC viability after exposure to paclitaxel. Day 7 DC were incubated with paclitaxel at 1-100 μM for 2 h, washed and returned to
culture for up to 120 h (5 days). Viability was assessed by trypan blue (and propidium iodide (PI) dye exclusion, data not shown). Representative
data from one of 3 individual donors are shown. No deleterious effect on survival was seen, (B). DC were exposed to paclitaxel at 1-100 μM for
2, 24 or 48 h and viability assessed at the end of 48 h by PI dye exclusion. Short-term exposure of DC to paclitaxel had no effect on viability,
however, 100 μM paclitaxel for 48 h did induce a significant loss in viability (* P < 0.05).
Table 1 Expression of DC surface markers in response to
paclitaxel.
Taxol(μM)
Marker No Drug LPS 1 10 100
HLA Class II 625 1265 690 888 1109
HLA Class I 93 274 95 85 87
CD40 4 7 6 6 7
CD80 40 95 57 61 51
CD83 5 22 4 5 4
CD86 18 71 27 26 33
DC were incubated with paclitaxel at various concentrations or LPS (1 μg/ml)
for 2 h before being washed and returned to culture for a further 24 h.
Surface expression of various molecules was assessed by flow cytometry as
outlined in the materials and methods. The panel reports the delta MFI (the
difference between isotype-matched mAb and specific mAb) mean
fluorescence intensity (MFI). Data representative of 5 independent
experiments.
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increase was seen with a 3-fold increase in proliferation
with DCs treated with 10 μM and 2-fold increase with
DCs treated with 1 μM. This enhancement in prolifera-
tion was maintained at all ratios of T cell:DC tested.
Paclitaxel reduces receptor-mediated endocytosis
As already demonstrated, the exposure of DC to pacli-
taxel induced HLA class II expression but not other
markers including the mannose receptor CD209 (data
not shown). This was reflected by similar levels of dex-
tran-FITC binding to the cell surface receptor of quies-
cent DC incubated at 4°C figure 4. However, during
active endocytosis at 37°C an increase in the concentra-
tion of paclitaxel caused a decrease in the endocytic
capacity of treated DC. At concentrations above 10 μM
the level of uptake was significantly reduced by at least
a 1.5-fold change in MFI when compared to untreated
DC (P < 0.05 at 10 μmol), figure 4.
Microarray analysis
The effect of paclitaxel and LPS on day 7 DC were
examined by microarray. All microarray data was depos-
ited in Array express (accession number E-MEXP-2465,
experiment name Pandha DC taxol). Duplicate samples
were compared. Fold changes in gene expression com-
pared to untreated cells are shown in table 2. Only sig-
nificant differences with p < 0.01 are shown. As
expected the most significant effects were observed with
LPS with induction of Th1 cytokine and chemokine
gene expression, STAT1 activation and CD69, a marker
of T cell activation. Other findings included an increase
in cell cycle gene p21, FAS and FAS ligand, receptors
such as ICAM1 and CXCR4, interferon alpha response
genes IFI27 and NFB. In contrast, paclitaxel reduced
the expression of most of these genes apart from IL-1al-
pha. LPS induced TLR2 expression but resulted in
marked reduction in TLR4 expression: paclitaxel was
associated with a moderate reduction in expression of
TLR2.
Figure 3 Enhanced DC immunostimulatory capacity at low dose Paclitaxel. Day 7 DC were treated with paclitaxel for 2 hours before being
co-cultured with allogeneic T cells at different cell ratios in a 5 day MLR. The proliferation of the T cells was determined by the incorporation of
[
3H] thymidine and the data shown are the mean S.I. ± SD of triplicate samples, and is representative of 3 independent experiments using DC
from 3 different donors. (* P < 0.05).
Figure 4 DC exposed to paclitaxel have less endocytic function
shown by uptake of FITC-conjugated dextran. Control and
paclitaxel treated DC were incubated with FITC-dextran for 2 h at
either 37°C (black bars) or 4°C (white bars). DC were washed with
ice cold PBS to remove unbound FITC-dextran prior to FACS
analysis. Combined data from 3 separate donor experiments are
shown. Increasing doses of paclitaxel significantly reduced active
endocytosis compared to no taxol exposure (P < 0.05 with 10 μmol
taxol exposure).
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LPS-treated DC
DC produced an array of inflammatory cytokines in
response to LPS stimulation. In keeping with the micro-
array findings, the addition of paclitaxel inhibited the
expression of IL-12p70, TNFa,I L - 1 0 ,I L - 8a n dI L - 1 b at
all concentrations tested (Figure 5A-E)
Paclitaxel induces actin remodelling of DC cytoskeleton
In the absence of LPS or paclitaxel immature DC were
characterised as being relatively large, irregular shaped
bodies with a readily visible dense network of microtu-
bules often focusing around the centrosome, figure 6(A).
The treatment of DC with 1 μM paclitaxel resulted in
distinct alterations to both DC morphology and micro-
tubule distribution. Many of the DC became rounded
with evidence of microtubule stabilisation, figure 6(B).
The changes in DC cytoskeleton organisation were even
more dramatic with 100 μM paclitaxel where all cells
appeared small, rounded with microtubules that were
no longer focused around the centrosome figure 6(C).
Maturation in response to 1 μg/ml LPS also induced a
rapid reduction in the size of the DC to smaller rounded
cells with many forming small clumps figure 6(D).
Again, the microtubules were less distinct and paralleled
than observed for the paclitaxel treated DC. Treatment
of LPS matured DC with various concentrations of
paclitaxel had no distinguishable effects on morphology
or microtubule stabilisation when compared to LPS
alone or high dose paclitaxel treated DC (data not
shown).
Effects of paclitaxel are not mediated via TLR-4 binding
We have demonstrated that the treatment of DC with
paclitaxel induces a dose dependent upregulation of sur-
face HLA-class II expression. In order to determine
Table 2 Microarray analysis of DC exposed to LPS 1 μg/
ml or paclitaxel 100 μM for 2 hours.
Name Accession number Taxol LPS
Cytokines IL6 NM_000600 0.625 13.75
IL1B NM_000576 0.57 21.4
IL10 NM_000572 0.14 1.3
IL18 NM_001562 0.44 4.77
IL1A NM_000575 2.33 2.5
TGFb NM_000660 0.5 0.43
CXCl12 NM_199168 1.428 42.3
Cell cycle CCND1 NM_053056 0.286 0.11
p21 NM_000389 0.875 3.125
ASK NM_006716 0.833 0.417
PCNA NM_002592 0.6 1.25
Apoptosis API4 NM_001012271 0.4 1
FAS NM_000043 0.667 6.22
CASP8 NM_033356 1.2 0.45
TNFRSF11B NM_002546 0.1 2.2
CASP3 NM_004346 0.7 3.3
TNFa NM_000594 0.4 3
FASLG NM_000639 0.375 5.625
Receptors ICAM1 NM_000201 0.667 3.77
TLR2 NM_003264 0.413 3.45
TLR4 NM_003266 0.769 0.078
CXCR4 NM_001008540 1 2
(Bold signifies upregulation)
Data shown is for samples where gene expression differed from untreated
cells (where P < 0.01). All microarray data was deposited in Array express;
accession number E-MEXP-2465, experiment name Pandha DC taxol.
Figure 5 Effects of Paclitaxel versus LPS on the ability of DC to
produce inflammatory cytokines. DC treated with LPS or
paclitaxel for 2 hours were extensively washed and returned to
culture for 24 h. Supernatants were collected and analysed by CBA
for the presence of A; IL-12; B, TNFa; C, IL-10; D, IL-1b; EIL - 8.
Overall, paclitaxel appeared to reduce cytokine secretion by DC
compared to LPS; significant increases of IL-1b secretion were seen
at lower doses of paclitaxel.
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we employed a blocking antibody against the TLR-4
molecule. Whilst LPS and paclitaxel induced the upre-
gulation of surface class II molecules, blocking of TLR-4
with a specific monoclonal antibody only partially inhib-
ited the response to LPS, figure 7.
Discussion
Several chemotherapeutic agents have been shown to
have dose dependent immunostimulatory activity [23].
However, there is conflicting data to suggest that these
compounds are also capable of inhibiting the generation
and maturation of cells capable of antitumour effects,
especially in cancer patients who are already debilitated
by their disease [24]. Paclitaxel is a widely used
cytotoxic agent which targets microtubules and induces
cellular death via apoptosis. The doses of paclitaxel
under evaluation in this study reflect clinical practice:
paclitaxel disappearance from plasma after intravenous
infusion is biphasic; half-lives of the first and second
phases occur approximately 0.3 and 8 hours, respec-
tively. The peak plasma concentration with a high dose
such as 275 mg/m
2, occurs immediately post-infusion,
and is approximately 8 μM [25]. We have demonstrated
that, at similar plasma levels as in clinical practice, the
mitochondrial function of human DC is less susceptible
to inhibition by paclitaxel when compared to cancer cell
lines. This is in accordance with data published on mur-
ine DC which were more resistant to paclitaxel com-
pared to the murine melanoma cell line B16 [26]. The
Figure 6 Paclitaxel induced alterations to DC morphology and cytoskeletal organisation similar to LPS. DC were adhered to fibronectin-
coated coverslips prior to treatment with LPS +/- Paclitaxel for 2 h. The cells were extensively washed before being stained for microtubule
arrangements and analysis by microscopy. Representative figures from 4 experimental repeats are shown. A, non-treated DC; B; 1 μM paclitaxel;
C, 100 μM paclitaxel; D, 1 μg/ml LPS. In keeping with its known action, exposure to paclitaxel resulted in microtubule stabilisation but marked
changes in DC morphology reduction in cell size, rounding and loss of dendrites.
John et al. BMC Immunology 2010, 11:14
http://www.biomedcentral.com/1471-2172/11/14
Page 6 of 11Figure 7 Upregulation of DC class II expression by paclitaxel is not mediated via TLR-4. DC were cultured for 2 h with LPS or paclitaxel in
the presence or absence of anti-TLR-4 Abs prior to washing and reculture for a further 24 h. Anti-TLR4 antibody did reduce class II expression
after exposure to LPS, but not to paclitaxel at high dose. Numbers in parenthesis represent MFI of class II detection. Data is representative of
3 independent experiments from 3 donors.
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of necrosis or apoptosis in murine DC treated with
paclitaxel for 24 hours. A recent publication indicated
significant effects of paclitaxel on DC at a dose range of
1-5 μMa l b e i to nm u r i n eD C s[ 2 7 ] .W ef o u n d ,b yt w o
different methods, that paclitaxel at 100 μMd o e sn o t
induce either immediate cellular death or reduce DC
viability for up to 5 days in culture. In contrast, it has
been reported that human DC can undergo apoptosis
following incubation with Paclitaxel at concentrations
above 10 μM when continually exposed for 24 hours
but these cells still maintaining mitochondrial function
[28].
O n ep o s s i b l em o d eo fa c t i o nb yw h i c hc h e m o t h e r a -
peutic agents may be immunomodulatory is by the
induction of DC maturation by the upregulation of key
molecules, especially those involved in antigen presenta-
tion such as HLA class II. We found that paclitaxel
selectively enhanced the expression of HLA class II on
DC in a dose dependent manner. Interestingly, the upre-
gulation of class II did not correlate with allo-stimula-
tory activity. Enhancement of the allo-stimulatory
activity was observed at low doses of paclitaxel which
was superior to LPS activated DC. This would suggest
that factors other than antigen presentation molecules
are crucially affected by treatment with higher doses of
paclitaxel. Low concentrations of paclitaxel have been
shown to have a cytostatic effect on cells by effecting
both cellular mitochondrial membrane and reducing
potential. However, the apoptotic pathway is stopped
upstream of mitochondria permeabilization and there-
fore does not lead to cell death[29]. The interactions of
MHC class II and the mitochondria are central during
the induction of mature DC death via cross linking of
the surface molecules [30]. The expression of MHC
class II in blood mononuclear cells is also associated
with the presence of Myosin-V which is itself frequently
associated with the central microtubules [31]. Therefore,
alteration in MHC class II expression may be due to
either paclitaxel induced disruption of mitochondrial
function or the effect on microtubule arrangement via
the co-localization with Myosin-V.
A reduction in the endocytic function of DC was also
observed in response to paclitaxel despite no overall
change in the expression of the specific surface receptor
CD209. Phagocytosis of Listeria monocytongenes by
macrophages has been shown to be dependent on func-
tional actin filaments. Depolymerising drugs such as col-
chicine and nocodazole greatly reduced the cells ability
to phagocytose L. monocytogenes while the stabilization
of microtubles with paclitaxel had no significant effect
on uptake [32]. Paclitaxel may therefore inhibit receptor
mediated endocytosis by preventing mitochondrial activ-
ity from facilitating this active process. We have
demonstrated that paclitaxel was very potent at altering
both DC morphology and microtubule organization.
Paclitaxel treatment in patients results in the release
of a spectrum of pro-and anti-inflammatory cytokines,
but most significantly IL-10, IL-8 and IL-6 [33]. Micro-
array analysis of DC after paclitaxel exposure showed
downregulation of most cytokine gene expression; the
overall effects of paclitaxel appeared to be anti-inflam-
matory. Cytokine analysis from supernatants reflected
these findings. In contrast, as expected, LPS effects on
DC were profoundly pro-inflammatory. Of note also was
the reduction in IL-12 production after exposure to
paclitaxel suggests that paclitaxel-treated DC may
induce a Th2 (or Th17) cell bias with implications
regarding their use therapeutically. Similarly, the lack of
chemokine secretion after paclitaxel exposure implies a
reduction in DC migration to lymph nodes thereby
reducing the possibility of priming naive T cells in a DC
therapy context.
The reduction of mitochondrial potential in DC
responding to glucocorticoid has been shown to inhibit
DC maturation and IL-12 production [34]. As with
MHC class II expression, depolarisation of the micro-
tubule network can severely inhibit DC production of
IL-12 in response to a TLR-4 agonist due to the disrup-
tion of intracellular TLR-4 [35]. Therefore, yet again
paclitaxel-induced disruption of mitochondrial activity
or microtubule arrangement may explain the inhibition
of cytokine production.
Paclitaxel has been shown to mimic LPS activation of
murine macrophages in a cell cycle-independent man-
ner. Stimulation of these primary cells with paclitaxel is
a TLR-4 and MyD88- dependent pathway which aug-
ments the release of TNF and nitric oxide [36]. TLR-4
has been shown to physically associate with the MD-2
and it is this molecule that confers LPS-responsiveness
on TLR-4. The species-specific activity of paclitaxel is
determined by murine MD-2 and not human MD-2,
suggesting that MD-2 is the crucial element for recogni-
tion [37]. However, both we and others have demon-
strated that human and murine myeloid cells respond to
paclitaxel in a TLR-4 independent manner.
Conclusion
In conclusion, this study has increased our understand-
ing of the effects of a potentially immunomodulatory
chemotherapeutic agent on the modulation of DC. Pacli-
taxel has been shown to both enhance and inhibit many
functional capabilities of DC via inhibiting mitochon-
drial function and microtubule polymerization. Our pre-
liminary data suggests that these mechanisms may occur
in the absence of signaling through TLR-4. In the clini-
cal scenario, overall, we would anticipate that concomi-
tant administration of paclitaxel would enhance
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expression and increased allostimulatory activity of DC
although the precise time of administration of vaccine
and paclitaxel need to be carefully considered in view of
paclitaxel’s rapid distribution post-infusion. Combined
paclitaxel and DC-based vaccines are currently under
investigation in a murine model.
Methods
Antibodies
The following antibodies were purchased from Serotec,
Oxford, UK; HLA-ABC FITC HLA-DR,-DP,-DQ FITC;
CD80 PE; CD86 PE, CD40 PE and anti-tubulin. The fol-
lowing antibodies were purchased from Becton Dickin-
son, Oxford, UK; CD83 FITC, CD197 PE and CD209
PE. The Alexa 488 conjugated anti-rat secondary anti-
body was purchased from Molecular Probes, Paisley,
UK. Anti-TLR4 blocking antibody was purchased from
Axxora, Nottingham, UK.
Cell lines
The MCF7-pR human breast cancer cell line (a gift from
Dr. Kay Colston, St George’s University of London, UK)
was grown in culture medium (CM) RPMI 1640; 10%
FCS; 1% Penicillin/Streptomycin and 2 mM L-Gluta-
mine all purchased from Sigma-Aldrich, Dorset, UK)
and incubated at 37°C in a humidified incubator at 5%
CO2. The melanoma cell line MJT-3 was previously
established in our laboratory from a brain metastasis of
a 45 yr old female patient [38] and cultured as outlined
for MCF7-pR.
Generation of monocyte-derived dendritic cells (DC)
Immature DC were prepared from peripheral blood
mononuclear cells (PBMCs) isolated from buffy coats
purchased from the blood bank. A minimum of 3 differ-
ent buffy coats were used for each experiment. PBMCs
were incubated with anti-CD14 microbeads (Miltenyi
BiotecBergish Gladbach, Germany) as specified in the
manufacturer’s instructions. The isolated monocytes
were resuspended at 10
6 cells/ml in medium supplemen-
ted with 10% human AB serum, 100 ng/ml GM-CSF
(Leucomax; Novartis, Camberley, UK) and 50 ng/ml IL-4
(Peprotech EC Ltd, London, UK), cultured in tissue cul-
ture flasks. On day 7 the cells were defined as immature
DC with low/intermediate HLA-DR expression
In vitro cell drug-sensitivity assay
MCF7-pR and MJT-3 cells were plated in 96 well flat
bottom plates at 5 × 10
4 cells/well in CM. Paclitaxel
(Bristol Myers Squibb, Princeton, US) was serially
diluted in CM and added to the cells to give a final con-
centration range of 0-100 μM. Day 7 DC were plated at
10
5 cells/ml in CM. The cells were incubated for 2 h
and then washed twice by centrifugation with 200 μl
fresh CM to remove the presence of the drug. The cells
were allowed to recover in fresh medium for a further
48 h before the addition of MTS/PMS (Promega, Madi-
son, USA). Optical density (O.D.) at 490 nm was mea-
sured after a further 2 h incubation using a Dynex
technologies MRX-II plate.
The percentage cell viability was calculated as;
% Viability = 100 × (absorbance of cells incubated
with drug containing medium)/(absorbance of cells
incubated with medium alone).
DC viability assessment
DC viability was assessed after 48 h post incubation in
the presence of paclitaxel at various concentrations for
2, 24 or 48 h of the treatment. At the end of the 48 h
the cells were harvested, washed twice and resuspended
in PBS for TB enumeration by light microscopy or PBS
containing PI (Sigma-Aldrich) for analysis by flow cyto-
metry. Viable cells were verified and enumerated
depending on their ability to exclude TB or PI. The per-
centage of viable DC was calculated as outlined above.
Direct surface staining for immunophenotyping
DC were harvested and washed in wash buffer (PBS
containing 0.5% BSA and 0.1% sodium azide, all pur-
chased from Sigma-Aldrich). Cells were labeled with the
relevant fluorochrome-conjugated antibody at the con-
centration recommended by the manufacturer for
30 min on ice in the dark. DC were also incubated with
an irrelevant isotype-matched control antibody to com-
pensate for non-specific binding. The cells were then
washed in wash buffer and the cell pellet fixed with
200 μl CellFix (Becton Dickinson). Samples were either
analysed immediately or within 24 h (stored at 4°C in
t h ed a r k )o naf l o wc y t o m e t e r . Routinely 10,000 events
were collected with dead cells and debris being gated
out on the basis of their light scatter properties.
Mixed Lymphocyte Reaction (MLR)
The stimulatory function of the drug-treated DC was
assessed by their ability to induce proliferation in allo-
geneic non-adherent PBMCs. Day 7 DC were incubated
i nt h ep r e s e n c eo fp a c l i t a x e lf o r2ha sp r e v i o u s l y
described. The cells were washed, resuspended in CM
a n dg r a d e dn u m b e r so fD Cc o - c u l t u r e dw i t h1 0
6 allo-
geneic non-adherent PBMCs. Proliferation was mea-
sured on day 5 following 18 h of pulsing with 1 μCi
[
3H]-Thymidine per well. Mean values of triplicates
were measured and expressed as stimulation indices (SI).
SI = (mean counts per minute for test sample)/(mean
counts per minute of background)
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The endocytic capacity of DC was determined as fol-
lowed. Briefly, DC were treated as before with various
concentrations of paclitaxel for 2 h prior to incubation
at 4°C or 37°C for 10 min in CM to equilibrate the tem-
perature. Dextran-FITC (40,000 MW- Sigma-Aldrich)
was added to each sample and incubated for a further
60 min at the same temperature. Washing the cells
twice in ice cold PBS quenched the endocytic activity
and removed any free dextran-FITC. Cells were fixed in
200 μl of CellFix and routinely 5000 cells were analysed
by flow cytometry. Surface only binding of dextran-
FITC was deemed to occur when the DC were incu-
bated at 4°C while endocytosis was judged to occur at
37°C.
Measurement on cytokine production
IL-12p70, TNFa, IL-10 and IL-1b were analysed using the
cytometric bead array (Becton Dickinson). Supernatants
were collected from DC after treatment with LPS (1 μg/ml)
or Paclitaxel for 2 h followed by re-culture for 24 h. The
supernatants were frozen at -20°C until analysis.
Actin-remodelling in DC
Coverslips were washed in 70% ethanol for 10 min, fol-
lowed by brief washes in 95% and then 100% ethanol
before air drying. Coverslips were inverted in 50 μg/ml
fibronectin solution (Sigma-Aldrich) for 2 hours. Cover-
slips were rinsed extensively in PBS, placed in the wells
of a tissue culture plate and covered with CM. Imma-
ture DC or LPS-matured DC were seeded on the fibro-
nectin-coated coverslips for 1 hour. Cells were then
treated with paclitaxel at a final concentration of 0-100
μM as required for 2 hours prior to fixation and immu-
nocytochemistry. DC were washed twice in PBS before
incubating in -20°C methanol for 5 min. Cells were
blocked for 30 min in blocking buffer (PBS containing
1% non-fat dried milk) before incubation with anti-tubu-
lin antibody for 1 hour. DC were washed in PBS before
incubation with an Alexa 488 conjugated anti-rat sec-
ondary antibody for 1 h. Coverslips were washed before
mounting on glass slides using Mowiol (Calbiochem,
Nottingham, UK). Images were captured using a Zeiss
Axiovert 200TV microscope connected to a Hamma-
matsu camera and imported into Imaris. Images were
exported to and figures assembled in Adobe Photoshop.
Blocking of TLR-4 receptor
DC were cultured with LPS (1 μg/ml) or paclitaxel (100
μM )f o r2hi nt h ea b s e n c eo rp r e s e n c eo f4μg/ml of a
blocking antibody directed towards TLR-4. The cells
were washed before being returned to culture for a
further 24 h. Cells were assessed for the expression of
HLA DR as outlined above.
Microarray analysis of the effects of Paclitaxel and LPS
on DC
Total RNA was extracted from day 7 DC which had
been treated for 2 h with 1 μg/ml LPS or 100 μMp a c l i -
taxel for 2 h then washed and returned to culture for
24 h. This was used as a template to generate Cy3-
labelled cRNA, using the Low RNA Input Linear Ampli-
fication Kit (Agilent). This was used as a probe on the
Whole Human Genome Microarray (4 × 44 K) slide
(Agilent). Slides were scanned using the Agilent scanner
and data extracted using Feature Extraction Software
9.5.3 (Agilent). Subsequent data analysis was performed
using GeneSpring GX software.
Statistical analysis
The statistical significance of experimental data was
evaluated using the Student’s t-test where P <0 . 0 5w a s
considered as statistically significant.
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